MX344163B - Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas. - Google Patents

Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas.

Info

Publication number
MX344163B
MX344163B MX2012008301A MX2012008301A MX344163B MX 344163 B MX344163 B MX 344163B MX 2012008301 A MX2012008301 A MX 2012008301A MX 2012008301 A MX2012008301 A MX 2012008301A MX 344163 B MX344163 B MX 344163B
Authority
MX
Mexico
Prior art keywords
loratadine
formulation
encapsulation
combinations
dosage unit
Prior art date
Application number
MX2012008301A
Other languages
English (en)
Other versions
MX2012008301A (es
Inventor
Draper Peter
Okutan Beth
Draper James
Original Assignee
Accucaps Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accucaps Ind Ltd filed Critical Accucaps Ind Ltd
Publication of MX2012008301A publication Critical patent/MX2012008301A/es
Publication of MX344163B publication Critical patent/MX344163B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona a una formulación de loratadina adecuada para la encapsulación en una cápsula de gel blando o unidad de dosificación adecuada con funcionalidad mejorada que proporciona disolución y biodisponibilidad in vitro aumentada de loratadina. La invención también proporciona una formulación con funcionalidad mejorada como una solución altamente concentrada dentro de un volumen de llenado dado con el fin de fabricar una cápsula tan pequeña como sea posible para facilitar la aceptación del consumidor y costos de fabricación aceptables. La invención también se relaciona a una formulación de estabilidad óptima adecuada para soportar una composición de llenado compatible con la unidad de dosificación de cápsula de gel blando.
MX2012008301A 2010-01-19 2011-01-18 Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas. MX344163B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2690490A CA2690490C (en) 2010-01-19 2010-01-19 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
PCT/CA2011/000052 WO2011088550A1 (en) 2010-01-19 2011-01-18 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof

Publications (2)

Publication Number Publication Date
MX2012008301A MX2012008301A (es) 2012-09-28
MX344163B true MX344163B (es) 2016-12-07

Family

ID=44303619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008301A MX344163B (es) 2010-01-19 2011-01-18 Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas.

Country Status (17)

Country Link
US (1) US20120301544A1 (es)
EP (2) EP2525827B1 (es)
JP (1) JP5328992B2 (es)
AU (1) AU2011207058B2 (es)
CA (1) CA2690490C (es)
CY (1) CY1123895T1 (es)
DK (1) DK2525827T3 (es)
ES (1) ES2843351T3 (es)
HR (1) HRP20201923T1 (es)
HU (1) HUE053412T2 (es)
LT (1) LT2525827T (es)
MX (1) MX344163B (es)
PL (1) PL2525827T3 (es)
PT (1) PT2525827T (es)
RS (1) RS61362B1 (es)
SI (1) SI2525827T1 (es)
WO (1) WO2011088550A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103784399B (zh) * 2014-03-05 2015-09-30 大连金石滩药业有限公司 氯雷他定液体组合物
CN103784446B (zh) * 2014-03-05 2016-01-06 大连金石滩药业有限公司 氯雷他定组合物
JP7065562B2 (ja) * 2015-09-04 2022-05-12 ロート製薬株式会社 医薬組成物
KR101746500B1 (ko) 2016-05-26 2017-06-14 (주)알피바이오 연질캡슐 제제용 로라타딘 조성물 및 이를 함유하는 연질캡슐
WO2019113461A1 (en) 2017-12-08 2019-06-13 Western University Of Health Sciences Lipid emulsified drug delivery systems for chemoprevention and treatment
CA3100314A1 (en) 2018-05-16 2019-11-21 Bayer Healthcare Llc High concentration suspension formulation for cold and flu soft gel capsule medications
CN112426404B (zh) * 2020-10-29 2023-02-28 太阳升(亳州)生物医药科技有限公司 用于制备富马酸卢帕他定口服液的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
AU570306B2 (en) 1984-02-15 1988-03-10 Schering Corporation 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts.
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
US4900775A (en) * 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US4910205A (en) 1988-05-02 1990-03-20 Schering Corporation Transdermal delivery of loratadine
US4863931A (en) 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US4990535A (en) 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
WO1993002664A1 (en) * 1991-07-26 1993-02-18 Smithkline Beecham Corporation W/o microemulsions
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
CZ210496A3 (en) * 1994-01-24 1996-12-11 Procter & Gamble Method improving solution process of difficult-to dissolve pharmaceutically active compounds
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
HUT76051A (en) * 1994-04-07 1997-06-30 Smithkline Beecham Plc Halofanthrine free base for the treatment of malaria and compositions containing the same
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
ATE429210T1 (de) * 1998-01-20 2009-05-15 Applied Analytical Ind Inc Orale flüssige zusammensetzungen
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
ES2226289T3 (es) 1998-06-30 2005-03-16 Pfizer Products Inc. Loratadina para uso como antiarritmico.
US6221391B1 (en) * 1998-11-23 2001-04-24 Accucaps Industries Limited Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
DE60222803T2 (de) * 2001-12-21 2008-07-17 Supernus Pharmaceuticals, Inc. Orale kapselformulierung mit verbesserter physikalischer stabilität
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
JP2008534591A (ja) * 2005-03-29 2008-08-28 マクニール−ピーピーシー・インコーポレーテツド 疎水性溶媒内に親水性薬剤を有する組成物
WO2009066146A2 (en) * 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives

Also Published As

Publication number Publication date
SI2525827T1 (sl) 2021-02-26
EP2525827A1 (en) 2012-11-28
EP2525827A4 (en) 2014-04-30
JP2013517303A (ja) 2013-05-16
EP2525827B1 (en) 2020-11-18
MX2012008301A (es) 2012-09-28
LT2525827T (lt) 2021-03-25
PL2525827T3 (pl) 2021-05-04
ES2843351T3 (es) 2021-07-16
CA2690490A1 (en) 2011-07-19
HRP20201923T1 (hr) 2021-02-05
HUE053412T2 (hu) 2021-06-28
WO2011088550A1 (en) 2011-07-28
EP3653204A1 (en) 2020-05-20
AU2011207058A1 (en) 2012-09-06
CA2690490C (en) 2012-06-26
JP5328992B2 (ja) 2013-10-30
CY1123895T1 (el) 2022-05-27
AU2011207058B2 (en) 2015-04-23
US20120301544A1 (en) 2012-11-29
PT2525827T (pt) 2021-01-20
DK2525827T3 (da) 2020-12-14
RS61362B1 (sr) 2021-02-26

Similar Documents

Publication Publication Date Title
MX344163B (es) Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas.
IL244945A0 (en) Cationic lipid, lipid formulations including it and their use in the preparation of therapeutic agents for administration to cells
TN2010000152A1 (en) Pharmaceutical compositions
WO2011093823A3 (en) Effervescent formulations comprising cefaclor and clavulanic acid
HK1182010A1 (en) Liquid pharmaceutical composition for the delivery of active ingredients
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
IL218165A (en) Stable Pharmaceutical Formulations Highly Concentrated to Provide Subcutaneous Active Pharmaceutical Antibody against CD20
WO2011146876A3 (en) Oral transmucosal administration of sufentanil
IL220465A0 (en) Methods and compositions for stable liquid drug formulations
MX348823B (es) Formulaciones estables de linaclotida.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
MX358636B (es) Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas.
MX2012002831A (es) Formulaciones para suspension oral de acetato de esclicarbazepina.
IL213671A (en) Pharmaceutical preparations containing alglitazar, a process for their preparation and use for the preparation of medicines
ZA201500410B (en) Formulations for the preparation of immediate-release tablets for oral use containing low-dose mifepristone for the treatment of endometriosis, tablets thus obtained and their preparation process
PT2568970T (pt) Formulações farmacêuticas estáveis contendo um anti-histamínico
WO2011095801A3 (en) Liquid pharmaceutical composition for buccal administration comprising morphine
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
ZA201500411B (en) Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process
GB201008049D0 (en) Composition
TW200833375A (en) Pharmaceutical compositions
GB201005204D0 (en) Improvements in heterotypic formulations of anticancer drugs
EP2436383A4 (en) ORAL ACETIC COMPOSITION AND ORAL CAPSULE WITH THE INGREDIENTS COMPRISED THEREOF
GB0811684D0 (en) Improvements in heterotypic formulations of anticancer drugs
AU2007902112A0 (en) Nanoparticle-coated capsule formulation for dermal drug delivery

Legal Events

Date Code Title Description
FG Grant or registration